Leukemia is majorly treated by topoisomerase inhibitors that induce DNA double strand breaks (DSB) resulting in cell death. Consequently, modulation of DSB repair pathway renders leukemic cells resistant to therapy. As we do not fully understand the regulation of DSB repair acquired by resistant cells, targeting these cells has been a challenge. Here we investigated the regulation of DSB repair pathway in early drug resistant population (EDRP) and late drug resistant population (LDRP). We found that doxorubicin induced equal DSBs in parent and EDRP cells; however, cell death is induced only in the parent cells. Further analysis revealed that EDRP cells acquire relaxed chromatin via upregulation of lysine acetyl transferase KAT2A (GCN5). Drug treatment induces GCN5 interaction with ATM facilitating its recruitment to DSB sites. Hyperactivated ATM maximize H2AX, NBS1, BRCA1, Chk2, and Mcl-1 activation, accelerating DNA repair and survival of EDRP cells. Consequently, inhibition of GCN5 significantly reduces ATM activation and survival of EDRP cells. Contrary to EDRP, doxorubicin failed to induce DSBs in LDRP because of reduced drug uptake and downregulation of TOP2b. Accordingly, ATM inhibition prior to doxorubicin treatment completely eliminated EDRP but not LDRP. Furthermore, baseline AML samples (n 5 44) showed significantly higher GCN5 at mRNA and protein levels in MRD positive compared to MRD negative samples. Additionally, meta-analysis (n 5 221) showed high GCN5 expression correlates with poor overall survival. Together, these results provide important insights into the molecular mechanism specific to EDRP and will have implications for the development of novel therapeutics for AML.
Leukemia chemotherapy involves drugs that inhibit topoisomerases to induce DNA double strand breaks (DSBs) in rapidly dividing cells. However, despite initial remission most of patients experience relapse. 1 Apart from mechanisms like downregulation of topoisomerases 2 and upregulation of drug transporters, 3 modulation of DNA repair pathway is known to play a major role in acquiring drug resistance in different cancer types. 4, 5 As topoisomerase inhibitors induce DNA DSBs, we focused on understanding the regulation of DNA repair mechanisms in chemoresistant leukemic cells.
ATM, a master regulator kinase involved in DNA DSBs repair, 6 is known as an important mediator of drug resistance. [7] [8] [9] Although ATM can get activated by autophosphorylation, mechanisms like higher recruitment via Mre11 proteins, relaxed chromatin architecture, downregulation of its phosphatases (WIP1 and PP2CA), direct acetylation by TIP-60-and HMOF-induced H4K16ac-mediated recruitment 6, [10] [11] [12] [13] [14] [15] have been shown to further enhance its activity. Extensive research on understanding the role of DNA DSB repair in chemoresistance in leukemia has been done using cell lines with high-resistance indices-based model systems. As these model systems cannot be used for comparative studies between the early and late stages of drug resistance, there is limited knowledge regarding the evolution of DNA repair mechanism during acquired resistance. Therefore, we developed in vitro cellular models that allowed us to examine regulation of DNA repair from an initial drug-tolerant state to late drug-resistant state. We found that with continuous drug treatment, LDRP evolved such that topoisomerase inhibitors failed to induce significant DNA damage and ATM activation, rendering these cells ineffective against ATM inhibitor. However, during early stages of acquired resistance GCN5/KAT2A (a lysine acetyltransferase) was upregulated in chemoresistant leukemic cells. Upon drug treatment GCN5 facilitated higher ATM activation leading to faster DNA repair. Inhibition of GCN5 inhibited ATM activation and sensitized EDRP to doxorubicin treatment thus demonstrating that targeting early events during acquired resistance would have maximum clinical benefit. Furthermore, GCN5 expression could be used as a potential biomarker to detect onset of resistance during induction therapy. Accordingly, inhibition of GCN5 during early stages is a novel approach to prevent emergence of difficult to treat stable resistant leukemic clones.
Material and Methods
Cells lines, cell culture and vector transfections K562, THP-1, KG-1 and HL-60 cell lines were obtained from NCCS Pune, HL-60/MX2 cell line was obtained from ATCC (CRL 2257 TM ). All the cell lines were maintained in RPMI with 10% FBS and antibiotics. 293FT cells (a kind gift from Dr Amit Dutt, ACTREC) were cultured in DMEM with 10% FBS and antibiotics. Cell lines were authenticated by STR profiling using PROMEGA STR profiling kit using 10 markers (Supporting Information, Table 1 ). GFP-GCN5 was purchased from Addgene (plasmid # 65386). pEBB Flag GCN5 was a gift from Dr Ezra Burstein (UT Southwestern Medical Centre). 293FT cells were transfected with GCN5 overexpression vectors using lipofectamine 3000 reagent according to manufacturer's protocol.
Immunofluorescence/colocalization
Methanol-fixed cells were spread on coverslips. Cells were then permeabilized and blocked followed by overnight incubation with primary antibody. Following PBS washes, cells were incubated with secondary antibody (Alexa Fluor 488/ 633). Cells were mounted with vectashield mounting medium containing DAPI and imaged using Zeiss LSM 780 Confocal Microscope. For colocalization, 0.5 3 10 6 K562 cells treated with 2.5 lM of doxorubicin for 2 hr prior to fixing with 100% methanol for 2 hr in 2208C and dispensed on a polylysine coated coverslips. Dual staining with anti-GCN5 and anti-p-ATM (S1981) was performed as mentioned above. Staining was quantitated using ImageJ software.
Co-immunoprecipitation
THP-1 and Flag-GCN5 overexpressing 293FT cells were treated with doxorubicin for 2 hr. Cells were fixed with formaldehyde and then lysed in EBC lysis buffer. Approximately 300 lg of lysates were incubated overnight on rotating shaker at 48C with 5 lg GCN5 antibody and appropriate IgG Isotype control. Equilibrated agarose-G beads were added to immuno-complexes and incubated for 2 hr on rotating shaker at 48C. Immunoprecipitated proteins was loaded on 10% SDS-PAGE and probed with anti-GCN5 and anti p-ATM (S1981) antibodies.
HR and NHEJ vector reactivation assay
HR and NHEJ activity assay vectors were a kind gift from Dr Vera Gorbunova (University of Rochester Department of Biology). Cells were transfected with 1 mg of I-SceI endonuclease digested vectors with X-treme GENE HP DNA Transfection Reagent (Roche). Transfection was done in three biological replicates including Td-Red as transfection control. Flow cytometry was done 72 hr post transfection. Percent repair efficiency was calculated by taking ratio of % of GFP (HR or NHEJ) positive cells to % of Td-Red-positive cells.
Ethics statement and patient samples
Blood samples from AML patients were accrued after approval by the institutional ethics committee (TMC-IEC III) DCGI registration number: IEC III: ECR/149/Inst/MH/2013. A written informed consent was taken in language understood by the patients. Following FAB diagnosis, AML cases were characterized by immunophenotyping using multiparametric flow cytometry. Patient information is provided in Supporting Information, Table 4 . 
MTT assay and drugs

Western blotting
Cells were lysed in laemmli lysis buffer, proteins separated on SDS-PAGE and transferred on to nitrocellulose membrane. Membranes were probed with different primary antibodies (Supporting Information, Table 2 ). Blots were developed using ECL reagent (Thermo Fischer). Densitometric analysis was done using ImageJ software as per the instructions of the software manual. Western blot densitometric data are provided in Supporting Information.
SYBR green-based quantitative real-time PCR RNA was extracted using TRI Reagent (Thermo Fisher) and cDNA made using Superscript III First-Strand kit (Invitrogen). Quantitative real-time PCR was performed using SYBR green (Roche) in a Roche Life Cycler 480. GAPDH or RPL19 was used as internal control. Primer sequences are given in Supporting Information, Table 3 . 
Neutral comet assay
The protocol used for neutral comet assay was modified from E. Boutet-Robinet et al. 16 Briefly, 1 3 10 4 cells were mixed in LMPA at 428C, spread on agarose-coated slides and incubated with lysis buffer. Following electrophoresis, slides were dehydrated and stained with propidium iodide. Images were taken and comets scored using Open Comet software.
Transmission electron microscopy (TEM)
Cells were fixed with 3% glutaraldehyde and treated with 0.1% osmium tetraoxide. Subsequently, cells were dehydrated and treated with absolute alcohol, araldite A and araldite B. Sections of 70 nm were made and stained in 10% of alcoholic uranyl acetate incubated with lead acetate. The sections were imaged on transmission electron microscope (Jeol 1400 plus).
TEM image quantitation
Images were analyzed on the basis of their gray-scale intensity using MATLAB (Mathswork) computing software. To obtain the distribution of gray scale values at a given offset, the gray-level co-occurrence matrix (GLCM) was used. 17 siRNA knockdown of GCN5
THP-1 cells were seeded at 0.3 million/ml density per well in a 6-well plate and transfected with siRNA (Invitrogen Cat no. 4390824) at 30 pmols per well concentration using standard 6-well protocol for RNAiMax reagent. Cells were collected 72 hr post transfection and tested for GCN5 knockdown by western blotting.
AML bone marrow immunohistochemistry
Bone marrow sections of 4 mM thickness were fixed on poly-L-lysine-coated glass slides. Sections were rehydrated by passing through xylene and ethanol gradient for 10 min each. Tris-EDTA buffer (pH 5 9) was used for antigen retrieval with moist heat for 15 min. Sections were blocked with serum for 30 min at room temperature. Sections were incubated overnight with anti-GCN5 antibody at 1:100 dilution. After PBS washes, sections were incubated with secondary antibody tagged with Alexa 633 dye for 1 hr at RT. Unbound antibodies were removed by PBS wash and sections were mounted with mounting medium containing DAPI. Sections were imaged using Zeiss LSM 780 Confocal Microscope. Median fluorescence intensity was calculated using ImageJ software.
Statistical analysis
The two-tailed Student's t test was applied for statistical analysis. Results were considered significant in all experiments at p < 0.05. When representing quantitative data, * means p < 0.05, ** means p < 0.01 and *** means p < 0.001.
RESULTS
Recapitulating clinical scenario of acquired resistance in a cellular model
We modeled acquired resistance to DNA damaging agent doxorubicin using leukemic cell lines K562 and THP-1. The overall schema for the development of the resistance model is shown in Figure 1a . First, the lethal dose (where 90% cells die) of doxorubicin for K562 and THP-1 was determined to be 2.5 and 1.4 mM, respectively, by cell viability assay (Figs. 1b and 1c). Cells were then treated with their respective lethal dose of doxorubicin for 48 hr. We found that a small percentage (<10%) of cells survived (persisters or residual cells, equivalent to the minimal residual disease observed in the patients) high concentrations of doxorubicin in both the cell lines. These persisters were allowed to grow. The first relapsed population (R) was termed K562-R1 and THP-1 R1. K562 cells were treated with doxorubicin for 10 cycles (over 8 months) while THP-1 for 7 cycles (over 6 months) to obtain the cells with the high drug resistance index. We collected the relapsed cells after every round of drug treatment, that is, R1, R2, R5, R7 and R10 for K562 and R1, R2, R3, R5 and R7 for THP-1 cell line. Resistance to doxorubicin for each population was analyzed by MTT cell viability assay (Figs. 1b and 1c). We found that R1 population of K562 and R1 and R2 population of THP-1 cell line showed similar sensitivity to doxorubicin as the parent population. However, K562-R2 cells (1.97-fold resistance) and THP-1-R3 cells (1.46-fold resistance) were earliest relapses that showed significantly better survival to doxorubicin than their respective parent populations (Figs. 1d and 1e). As K562-R2 and THP-1-R3 were the first populations to show significant resistance to doxorubicin, we refer to these populations as early drug resistant population (EDRP) cells and K562-R10
and THP-1-R7 as late drug resistant population (LDRP) cells. EDRP and LDRP of both the cell lines were analyzed for their clonogenic ability in the presence of IC90 concentration of doxorubicin. As shown in Figures 1f and 1g , both EDRP and LDRP formed significantly higher number of colonies compared to parent cells, indicating the enrichment of cells with colony forming capacity (unlimited cell growth) in these populations. Similar results were obtained with HL-60 and its mitoxantrone-resistant subcell line HL-60/MX2 (representing LDRP of HL-60), which is 35-fold more resistant than parent HL-60 cells 18 (Supporting Information, Fig. 1a ). We further tested the cross resistance of K562, K-EDRP and K-LDRP to DNA-damaging drugs daunorubicin and cytarabine and found that both the populations were resistant to daunorubicin, whereas cytarabine resistance was shown only by K-LDRP ( Supporting Information, Fig. 1b) . Interestingly, the chemoresistant populations showed reversibility to resistance when cultured in drug-free media.
EDRP cells showed loss of resistance faster (10-12 days) than LDRP cells (30-40 days) ( Supporting Information, Fig. 1c) . Similarly, chemoresistance is shown to be reversible in HL-60/MX2 cells as well (ATCC CRL 2257). These data are suggestive of nongenetic mechanisms of acquired chemoresistance, especially during early stages of drug resistance.
EDRP shows faster DNA repair while LDRP do not incur significant DSBs post doxorubicin treatment
To investigate the alteration in DNA repair, we first checked for double strand breaks (DSBs) induced by doxorubicin at different time points (5 min, 6 hr, and 12 hr) post drug removal (PDR) using neutral comet assay (Fig. 2a) . Interestingly, LDRP showed minimal induction of DSBs while EDRP populations from both the cell lines (K562 and THP-1) showed DSBs similar to the parent population (Figs. 2b and  2c) . However, by 12 hr EDRP could resolve most of DSBs compared to parent cells suggesting faster DNA repair. Similar to LDRP of K562 and THP-1 post mitoxantrone treatment, HL-60/MX2 cells also induced minimal DNA DSBs (Fig. 2d) .
Phosphorylation of H2AX is the first cellular response to the induction of DSBs and the rate of appearance and resolution of g-H2AX is considered to be a measure of DSB repair efficiency of a cell. 19 Therefore, we analyzed the activation of g-H2AX at different time points following the drug treatment. We found that immediately after drug removal compared to the parent cells, EDRP cells showed increased H2AX phosphorylation which was mostly resolved by 12 hr PDR (Figs. 2e and 2g) confirming faster DNA repair in EDRP cells. Concordant with comet assay, LDRP cells showed significantly less induction of g-H2AX indicating inability of doxorubicin to induce DNA DSBs in these cells (Figs. 2f and 2h) . Similarly, HL-60/MX2 cells also did not show significant induction of g-H2AX and p-Chk2 upon mitoxantrone treatment (Fig. 2i ). These data demonstrate that topoisomerase inhibitors were unable to induce DSBs in LDRP cells. We then sought to elucidate the mechanism of DSB repair in EDRP cells.
EDRP harbors hyperactive ATM kinase signaling
Because cell cycle arrest and DNA repair is interlinked, we analyzed cell cycle profile of parent and EDRP with and without doxorubicin treatment. Post drug treatment, K562 and THP-1 parent and respective EDRP cells showed S and G2/M arrest at 24 and 48 hr, respectively. Although, the parent populations remained arrested, EDRP cells could overcome S and G2/M cell cycle arrest (Fig. 3a and Supporting  Information, Fig. 2a) . Similarly, mitoxantrone treatment induced cell cycle arrest in HL-60 cells but not in HL-60/ MX2 cells ( Supporting Information, Fig. 2b ). These data demonstrate that EDRP cells were able to resolve cell cycle arrest and do not elicit an apoptotic response.
ATM (ataxia telangiectasia mutated) is a sensor kinase that phosphorylates H2AX following DNA DSBs. 6 To investigate whether increased g-H2AX in EDRP cells could be attributed to ATM activation, levels of p-ATM were analyzed at different time points post doxorubicin treatment. Concordant with g-H2AX activation kinetics, immunofluorescence and western blot analysis of p-ATM showed >2-fold increase 
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in ATM activation in K-EDRP compared to the parent K562 cells (Figs. 3b and 3c) . Furthermore, downstream targets of ATM, like p-NBS1 (Ser343), p-BRCA1 (Ser1524) and p-Chk2 (Thr68), also showed higher activation in EDRP cells compared to the parent K562 cells (Fig. 3d) . Additionally Mcl-1 L, an antiapoptotic protein, whose expression is controlled by ATM 20 showed upregulation in K-EDRP cells ( Supporting Information, Fig. 2c ). Similar results were obtained for parent THP-1 and T-EDRP (Fig. 4e) . We then wanted to assess the choice of repair pathway (HR or NHEJ) and its efficiency in EDRP cells, for which we used HR and NHEJ vector activity assay. 21 Results showed significantly higher HR activity in K-EDRP cells compared to K562 cells (Fig. 3f) . Furthermore, we also found higher recruitment of Rad51, an HR-specific protein in K-EDRP compared to the parent K562 (Supporting Information, Fig. 3a ), these data are in agreement with previous reports where ATM is shown to prefer resolution of DNA DSBs via HR pathway. 22 
ATM kinase inhibition eliminates EDRP but not LDRP cells
The data presented above demonstrates hyperactivation of ATM during the onset of acquired resistance. Accordingly, inhibition of ATM should induce death in residual cells and prevent emergence of chemoresistance. To test this, parent cells, EDRP and LDRP of K562 and THP-1 were treated with 10 lM of ATM kinase inhibitor (KU55933) 23 in combination with different concentrations of doxorubicin (0-10 mM). ATM kinase inhibitor induced complete cell death in K-EDRP at 2.5 mM doxorubicin concentration but only 40% cell death in K-LDRP cells. Importantly, ATM inhibitor reduced the IC90 concentration of doxorubicin for K-EDRP from 6.93 to 1.39 lM. Similar results were obtained with THP-1 EDRP and LDRP ( Fig. 4a and Supporting Information, Fig. 4a ). As expected, ATM kinase inhibitor in combination with mitoxantrone did not show significant cell death in HL-60/MX2 cells (Fig. 4b) . Specificity of ATM kinase inhibitor was confirmed by quantification of p-ATM and p-Chk2 (Fig. 4c) . The differential response of EDRP and LDRP cells to ATM kinase inhibitor is attributed to the fact that, only EDRP but not LDRP cells show the activation of ATM with doxorubicin treatment (Figs. 4d and 4e ). This was expected as the LDRP cells showed minimum DNA damage to the drug treatment. To understand how LDRP cells escape DNA damage, we reasoned that this could be because of loss of its molecular target or over expression of drug efflux proteins. Therefore, we checked the expression of TOP2b (molecular target of doxorubicin and mitoxantrone) and drug efflux pump protein ABCB1 (MDR1) in all the three population of cells: parent, EDRP and LDRP. No significant differences were seen in the transcripts of TOP2b in parent and EDRP. However, TOP2b was found to be significantly downregulated in LDRP of both K562 and THP-1 cell line ( Fig. 4f and Supporting Information, Fig. 4b) . Similarly, HL-60/MX-2 cells also showed downregulation of TOP2b (Supporting Information, Fig. 4c ). We further examined the drug accumulation capacity of the parent, EDRP and LDRP of K562 and THP-1 cells. For which cells were treated with IC90 concentrations of doxorubicin and intracellular doxorubicin was measured using flow cytometry at 480 nm (excitation wavelength) and 570 nm (emission wavelength). 24 Intracellular drug concentrations were found to be comparable in parent and EDRP but reduced in LDRP cells indicating either 
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reduced uptake or faster efflux of drug by LDRP ( Fig. 4g and Supporting Information, Fig. 4d ). We found no significant difference in the transcript levels of ABCB1 (i.e., MDR1) in parent and EDRP, but they were markedly elevated in LDRP (Fig. 4h and Supporting Information, Fig. 4e ) suggesting that reduced drug accumulation in LDRP cells could be due to faster efflux of the drug. Collectively, these data showed that LDRP cells had evolved multiple mechanisms to escape drug induced DNA damage. However, given the central role of ATM activation in mediating chemoresistance in EDRP, we deemed it important to further understand the mechanism of higher ATM activation in EDRP cells.
EDRP cells show GCN5 upregulation
ATM activation is known to be controlled by the Mre11-Rad50-NBS1 (MRN) sensor complex. 10 However, we did not find either differential expression or recruitment of Mre11 between parent K562 and K-EDRP, ruling out the possibility of MRN complex mediating differential recruitment of ATM at DSBs in EDRP (Figs. 5a and 5b) . We then reasoned that downregulation of ATM phosphatases (WIP1 and PP2CA) could also maintain high levels of p-ATM. 6 However, no differences in the transcript levels of WIP1 and PP2CA in EDRP cells with respect to parent population were observed (Fig. 5c) . It is also known that chromatin relaxation triggers higher ATM activation. 6 We therefore did immunofluorescence staining for HP1 alpha (heterochromatin associated protein), indeed we found significant reduction in the levels of HP1 alpha in K-EDRP compared to the K562 population (Fig. 5d) . Additionally, transmission electron microscopy of the K562 and K-EDRP also confirmed euchromatization of K-EDRP (Fig. 5e ) cells compared to parent population. Open chromatin in K-EDRP was further confirmed by the presence of increased levels of H3K4me2 and downregulation of H4K20me2 and H3K27me2 (Fig. 5f ). HATs (Histone Acetyl Transferases) and HDACs (Histone deacetylases) are important in defining chromatin architecture and DNA repair response, 25 also higher expression of TIP60 and HMOF are known to activate ATM. Therefore, to define which HAT/ HDAC could be responsible for euchromatization in EDRP cells, we analyzed the transcript levels of P300, GCN5, TIP60, HMOF, HDAC and HDAC2 in all the chemoresistant populations. We found GCN5 to be overexpressed in all the different populations of chemoresistant cell lines (K562, THP-1 and HL-60) (Fig. 5g) .
To examine the expression of GCN5 in AML patient samples, peripheral blasts of 44 AML patients at baseline (at diagnosis) were collected and immunophenotypically characterized. Patient information is provided in Supporting Information, Table 4 . Immunophenotyping by multiparametric flow cytometry (MPFC) was used to classify these patients into MRD-positive and MRD-negative cohorts post induction and consolidation therapy. Baseline samples were then analyzed for GCN5 expression by SYBR green-based quantitative real-time PCR using RPL19 as internal control. Absolute Dct values were used to compare the expression differences of GCN5 between MRD-positive (n 5 22) and MRD-negative (n 5 22) patients (Fig. 6a) . We found that MRD-positive 
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patients had significantly higher expression of GCN5 compared to MRD-negative patient samples. Consequently, protein levels of GCN5 were also significantly higher in MRDpositive (n 5 18) AML baseline bone marrow biopsies compared to MRD-negative (n 5 11) samples as shown by immunostaining (Fig. 6b) . Additionally, we analyzed two AML microarray datasets GSE12417-GLP96(n 5 163) 26 and GSE5122(n 5 58) 27 using PrognoScan 28 and found that GCN5 overexpression significantly (minimum p values 5 0.000432 and p 5 0.046) correlates with poor patient survival ( Fig. 6c and Supporting Information, Fig. 5a ). These results suggest that GCN5 expression could be used to predict therapy response in AML patients.
GCN5-mediated ATM hyperactivation causes onset of acquired drug resistance in leukemia
Although GCN5 upregulation was associated with chemoresistant population, however, to analyze if GCN5 also contributed to the chemoresistance, we treated EDRP of K562 and THP-1 with different concentrations of GCN5 inhibitor (Butyrolactone 3) alone and in combination with doxorubicin. Indeed, inhibition of GCN5 significantly sensitized K-EDRP to doxorubicin. Importantly, Butyrolactone 3 had no effect on the viability of peripheral blood mononuclear cells (PBMCs) at 100 mM concentration (Fig. 6d and Supporting  Information, Fig. 5b ). Furthermore, GCN5 inhibition also sensitized K-EDRP cells to daunorubicin suggesting that GCN5 plays a role in resistance to daunorubicin ( Supporting  Information, Fig. 5c ). We next examined whether GCN5 inhibition is linked with ATM activation in leukemia cells. For this, we treated parent and EDRP cells with GCN5 inhibitor prior to doxorubicin treatment. As evident from Figure  6e and Supporting Information, Fig. 5d , GCN5 inhibition led to decreased p-ATM and p-Chk2 in doxorubicin-treated EDRP and parent cells. To confirm that decreased p-ATM was due to loss of GCN5 and not because of off-target effect of the inhibitor, we performed siRNA-mediated knockdown of GCN5 in THP-1 cell line. Indeed, THP-1 GCN5 knockdown cells showed reduced p-ATM post doxorubicin treatment compared to control siRNA (Supporting Information, Fig. 6a ). Similar results were also observed in HL-60, KG-1 (leukemic cell lines) and 293FT (nontransformed cell line) (Supporting Information, Figs. 6b and 6c) , demonstrating that interaction of GCN5 and ATM is not restricted to a specific cell type.
GCN5 colocalizes and interacts with ATM post doxorubicin treatment
To further confirm that GCN5 over expression can induce higher ATM activation, we overexpressed Flag-tagged and GFP-tagged GCN5 in 293FT cells. These cells when treated with doxorubicin showed higher ATM activation compared to doxorubicin treated non GCN5 overexpressing 293FT cells (Fig. 6f) . Next to understand, if the direct interaction of GCN5 with ATM enhances its recruitment, we first performed colocalization of GCN5 and p-ATM (S1981) in K562 cells following doxorubicin treatment. As seen from Figure 6gN5 and p-ATM showed overlapping foci, suggestive of their physical interaction. To further examine if GCN5 and ATM physically interact, we immunoprecipitated GCN5 from doxorubicin treated THP-1 and Flag-GCN5 overexpressing 293FT cells. As can be seen from Figure 6h , p-ATM (S1981) was co-immunoprecipitated with GCN5 from both the cell lines. These data confirm that GCN5 physically interacts with ATM kinase post doxorubicin treatment, although we cannot rule out the plausibility of other proteins in the complex that could be mediating the interaction of GCN5 and ATM. Taken together, this is the first study that shows GCN5 interacts with ATM and inhibition of GCN5 activity inhibits ATM activation.
DISCUSSION
Collectively, the data summarized in Figure 6i show that early drug-resistant cells survive by modulating DNA repair via higher activation of ATM kinase mediated by GCN5. Accordingly, these cells can be efficiently targeted by GCN5 and ATM inhibitors. In contrast, LDRP cells undergo several rounds of drug selection and acquire more than one bona fide drug-resistance mechanisms and therefore do not respond to ATM inhibitor. These findings provide a plausible mechanistic explanation for the failure of DDR inhibitors that are tested in clinical trial for the relapse, refractory and advanced stage patients.
We observed that both early and late acquired drug resistance was reversible in absence of drug, which indicates nongenetic routes of resistance. We demonstrate that modulation of DNA repair pathway is the first response of the cells toward development of resistance to DNA-damaging drugs and over multiple rounds of drug treatment, there is a gradual accumulation of molecular events that leads to difficult to treat highly resistant cells. At least during the early drug resistant stage as defined by our studies, there are no multiple clones with different mechanisms of resistance, because ATM inhibitor with doxorubicin in EDRP kills all the cells. However, we cannot rule out the fact that there are different mechanisms in different clones all requiring ATM activation for their survival. GCN5 is a lysine acetyl transferase involved in post translational modification of multiple histone and nonhistone proteins. GCN5 acts as a transcription activator and is a part of human ATAC and STAGA complex.
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GCN5 have been shown to interact with DNA repair proteins like DNA-PK, Ku70/80, H2AX 30 and also have been reported to be involved nucleotide excision repair. 31 This is the first report showing GCN5 is required for efficient ATM activation. However, our understanding of GCN5 and ATM interaction is inadequate and requires further investigation. This study identifies two important candidates (ATM and GCN5) that can be targeted during early stages of acquired resistance to prevent relapse. Recently, GCN5 is shown as potential therapeutic target against AML and ALL in vivo. 32, 33 Moreover, our data demonstrate GCN5 to be an important drug target that precludes leukemia drug resistance. Most importantly, we also demonstrate that GCN5 expression can be used as an indicator to detect onset of acquired drug resistance. We show that ATM inhibition in the EDRP along with doxorubicin not only induce apoptosis in EDRP but also significantly lower the concentration of doxorubicin required to induce complete cell death thus, increasing the efficacy of doxorubicin many folds. In conclusion, our data provides mechanistic explanation to clinical observations and demonstrate that preventing emergence of resistance by targeting early drug-resistant population would be more effective therapeutic approach in leukemia treatment. We believe that these findings are clinically significant and warrant further studies to establish their in vivo significance. 
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